Analysts Set Expectations for Gilead Sciences FY2027 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Erste Group Bank issued their FY2027 earnings per share (EPS) estimates for shares of Gilead Sciences in a note issued to investors on Wednesday, February 18th. Erste Group Bank analyst H. Engel forecasts that the biopharmaceutical company will earn $9.67 per share for the year. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

A number of other research firms have also recently weighed in on GILD. Mizuho increased their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Oppenheimer raised their price target on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Scotiabank lifted their price objective on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a research note on Wednesday, February 11th. Citigroup increased their target price on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Finally, Sanford C. Bernstein restated an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a report on Wednesday, February 11th. Twenty-three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $155.44.

Gilead Sciences Price Performance

Shares of GILD opened at $149.83 on Monday. The firm has a 50-day simple moving average of $134.07 and a two-hundred day simple moving average of $124.08. The stock has a market cap of $185.89 billion, a PE ratio of 22.13, a P/E/G ratio of 2.01 and a beta of 0.36. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $157.29. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Paulson Wealth Management Inc. lifted its holdings in shares of Gilead Sciences by 1.8% in the 4th quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 67 shares during the last quarter. Essex Financial Services Inc. increased its position in Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after buying an additional 71 shares during the period. Alpha Cubed Investments LLC increased its position in Gilead Sciences by 1.1% during the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after buying an additional 75 shares during the period. Personal CFO Solutions LLC lifted its stake in Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after buying an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares in the company, valued at approximately $18,577,278.72. The trade was a 18.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 319,891 shares of company stock valued at $45,091,556. 0.27% of the stock is owned by company insiders.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is presently 46.68%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx in a deal valued at about $7.8B (cash $115/share + $5 CVR), giving Gilead full control of Anito‑cel, a next‑generation CAR‑T for multiple myeloma that could reach regulators this year — a clear strategic boost to Gilead’s oncology franchise. Gilead Sciences to Acquire Arcellx
• Positive Sentiment: Sell‑side support: Needham reaffirmed a “buy” on GILD with a $170 price target, highlighting upside based on pipeline and M&A execution, which provides analyst backing for the medium‑term thesis. Analyst Reaffirmation (Benzinga)
• Neutral Sentiment: Gilead scheduled several investor‑conference presentations (TD Cowen, Leerink, Barclays) in early March — useful for management to frame the Arcellx rationale and provide pipeline / guidance color. Gilead to Present at Upcoming Investor Conferences
• Neutral Sentiment: Health‑care sector dynamics and a mixed broader market (including a late‑day drop in the Dow) are a moderating force — sector strength earlier in the session partly offset by broader risk‑off moves. Sector Update (Yahoo Finance)
• Negative Sentiment: A law firm (Kahn Swick & Foti) is investigating the Arcellx sale for adequacy of price and process, which raises the risk of litigation or a proxy fight that could complicate closing or create management distraction. Arcellx Investor Alert (BusinessWire)
• Negative Sentiment: Market concern about the premium and $7.8B price tag (deal cited as ~68–80% premium) is weighing on Gilead — investors are parsing near‑term cash/valuation impact, integration risk and whether the price fairly reflects risk for an outpatient oncology program. Deal Coverage (Reuters)

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.